Slide 1: Soligenix
((SOLIGENIX OTC QB: SNGX
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the comments of our management related thereto contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," “anticipates,” "believes," "intends,
Slide 3: Company Highlights
Company Highlights i=} iverse pipeline with multiple potential value drivers in development Innovative products addressing high unmet medical needs Experienced management and Board of Directors Expertise in specialized development areas of GI, oncology and biodefense Potential for co-development and
Slide 4: Development Candidates
Development Candidates BioTherapeutics Pha: Phase 3 SGX301 i Cutaneous T-Cell Lymphoma (CTCL) ei sail leh Ph. 3 data 2H 2016 sexo42 [RNIPSTIRAERDESIENATIONNN Ph. 2 data 1H 2015" Oral Mucositis in Head & Neck Cancer SGX203 Pediatric Crohn's Disease SGX201 Radiation Enteritis** ORPHAN/FAST TRACK DESIG
Slide 5: Multiple Potential Value Drivers
Multiple Potential Value Drivers scxot [eae |] [ee | PE | Ph. 3 study in CTCL SGxo42 Lae | 1H: P8 start Oral Mucositis SGX203 $GX201* VeloThrax™* OrbeShield™* * Potential value drivers dependent on continued government funding SOLIGENIX
Slide 6: Experienced Management and Board of Directors
Experienced Management and Board of Directors Christopher J Schaber, MSc, PhD President & CEO Richard Straube, MD Chief Medical Robert Brey, PhD Chief Scientific Oreola Donini, PhD VP, Preclinical R&D Joseph Warusz, CPA, MBA Acting Chief Financial Officer 25 years of experience Discovery Laboratorie
Slide 7: BioTherapeutics
BioTherapeutics ™ \ & Targeted Approach to Treating Oncology & Inflammation SOLIGENIX ’
Slide 8: BioTherapeutics Business Segment
BioTherapeutics Business Segment Commercial targets — unmet medical needs in oncology and inflammation Oncology SGX301 Oral Mucositis in SGX942 Head & Neck Cancer Oncology Supportive Care Oral BDP Acute Radiation (SGX201) Enteritis Cutaneous T-Cell Lymphoma Soligenix BioTherapeutics Segment Autoimmu
Slide 9: SGX301 — Synthetic Hypericin
SGX301 — Synthetic Hypericin First-in-class, represents new treatment paradigm -— safe, visible light activates topical SGX301 (synthetic hypericin) to treat disease Hypericin is one of the most powerful photosensitizers in nature Established Mechanism - Generation of Singlet Oxygen and Apoptosis Pa
Slide 10: Cutaneous T-Cell Lymphoma (CTCL)
Cutaneous T-Cell Lymphoma (CTCL) Class of Non-Hodgkin's Lymphoma (NHL) Caused by a mutation of T-cells Most NHLs are B-cell related Malignant, skin-trafficking T-cells are recruited to the upper dermis and epidermis (by virtue of expression of high levels of the chemokine receptor CCR4) Overview Two
Slide 11: SGX301 for CTCL
Phase 1 & 2 Clinical Trials Market Opportunity Development Plan ¢ (GOLIGENIX, SGX301 for CTCL First-in-class, proprietary composition represents new treatment paradigm — visible light with topical synthetic hypericin (skin-directed therapy) Phase 1 study in healthy volunteers demonstrated safety and
Slide 12: SGX301 — Phase 2 Response Rate
SGX301 — Phase 2 Response Rate Lesion Responses ynth llowing Six Weeks of Treat All Hypericin Responders 7/12 58.3%? Hypericin 0.25% Dose 5/9° 55.6% Hypericin 0.1% Dose 5/12 41.7%b Placebo Responder 1/12 8.3% Note: No serious adverse events other than mild phototoxicity at treated site a. Data refle
Slide 13: Clinical Efficacy
Clinical Efficacy Before and After - SGX301 and Visible Light CTCL Patch Hypericin Therapy CTCL Patch Pre-Therapy Using Visible Light Post -Therapy - (GOLIGENIX i
Slide 14: SGX94: Regulating the Innate Defense System
SGX94: Regulating the Innate Defense System Innate Immunity First-in- Class Innate Defense Regulator Robust Preclinical Package (SOLIGENIX First responder to infection and tissue injury Mobilizes anti-infective and tissue healing factors Mobilizes adaptive immunity May cause excessive inflammatory r
Slide 15: Oral Mucositis — Multi-Factorial Disease
Oral Mucositis — Multi-Factorial Disease Debilitating side effect of cancer chemotherapy and / or radiotherapy Massive ulceration of the mouth, tongue, soft palate and oropharynx Results in severe pain, inability to eat, reduced cancer treatment tolerance and significant increases in resource use an
Slide 16: Radiation-Induced Mucositis
Radiation-Induced Mucositis GOLD STANDARD Animal Model of Mucositis related to H&N Cancer + Decreased duration of mucositis by ~50% + Decreased peak severity from 3.4 to 3.0 50 oO iT] $ 40 46% reduction oO 5 «30 P<.001 oO a Q 20 a x 10 ie) Vehicle SGX942 Oral Mucositis Induced in Hamsters by Fractio
Slide 17: Chemo-Induced Mucositis
Chemo-Induced Mucositis PROTECTS against chemotherapy damage PROTECTS ALL mucosal tissue Duration of Severe Oral Mucositis Clinical Endoscopy Score R 25 = g 20 Day 4 Day 7 8 20 ed rl ———— a o o | _ 53% reduction 8 1.5: = ao 3 2 A 3 10 a > 2 S g 3 0.5 = 3 Ey & s = 0.0 VEHICLE SGX942 3 Vehicle SGX942
Slide 18: SGX942 for Oral Mucositis
Phase 1 Clinical Trial Market Opportunity Development Plan SGX942 for Oral Mucositis Proprietary composition administered as 4-min IV infusion — short plasma half-life, rapid tissue penetration and prolonged pharmacodynamic impact Phase 1 single and multiple ascending dose, double-blind, placebo-con
Slide 19: SGX942 — Other Development Targets
SGX942 — Other Development Targets Multiple potential targets in infectious disease and biodefense with opportunity for non-dilutive funding to support development Target Indication Potential Application (s) | Potential Funding Summary and Potential Next Steps Acute Bacterial Skin and _ Infectious d
Slide 20: Oral Beclomethasone 17,21-Dipropionate
Oral Beclomethasone 17,21-Dipropionate $GX201, SGX203 and OrbeShield™ are all independent product opportunities based on our orally administered proprietary formulation technology with beclomethasone 17,21-dipropionate (BDP) Each enables potent, topical corticosteroid effect to treat GI inflammation
Slide 21: SGX203 for Pediatric Crohn's Disease
SGX203 for Pediatric Crohn’s Disease Two tablet proprietary formulation of immediate and delayed release BDP Designed to treat inflammation throughout the Gl tract Positioned as a corticosteroid option with less toxicity than the current standard systemic steroid therapy — prednisone Overview Over 1
Slide 22: Vaccine/BioDefense
Vaccine/BioDefense Addressing Critical Concerns for Industry and Government SOLIGENIX
Slide 23: Vaccine/BioDefense Business Segment
Vaccine/BioDefense Business Segment Infectious Disease Vaccines ThermoVax™ Heat Stabilization Platform BioDefense Vaccines RiVax™ Ricin Vaccine Soligenix Vaccine / BioDefense Division BioDefense Vaccines VeloThrax™ Anthrax Vaccine * Funded by Government OrbeShield™ Gastrointestinal Acute (Oral BDP-
Slide 24: ThermoVax — Vaccine Thermostability Platform
ThermoVax™ — Vaccine Thermostability Platform Dried vaccine with desirable physical and immunogenic properties Improved stability and shelf-life at temperatures exceeding 40°C Positive Proof of Concept (POC) - 1 year stability data with no degradation Preservation of native protein structure Overvie
Slide 25: RiVax — Ricin Toxin Vaccine
RiVax™— Ricin Toxin Vaccine Produced as aluminum-adsorbed vaccine Efficacy against all routes of toxin exposure Statistically significant (p < 0.002) survival versus controls in non-human primate (NHP) lethal ricin toxin aerosol exposure model Induction of neutralizing antibodies and protection agai
Slide 26: OrbeShield for GI ARS
OrbeShield™ for Gl ARS Proprietary two tablet immediate and delayed release BDP formulation Multiple commercial scale cGMP batches manufactured with long-term controlled room temperature stability Overview Statistically significant survival post radiation exposure versus controls in canine model of
Slide 27: SGX101 for Melioidosis
SGX101 for Melioidosis Melioidosis is caused by Burkholderia pseudomallei (Bps) Frequently resistant to antibiotic treatment High mortality and relapse rate, despite prolonged therapy Exclusive Channel Collaboration with Intrexon Corporation Development of human monoclonal antibody (mAb) technology
Slide 28: Significant WW Market Potential
Significant WW Market Potential Oral Mucositis in H&N Cancer 90,000 Patients US 90,000 Patients EU 20,000 Patients US 20,000 Patients EU Pediatric Crohn’s Disease 80,000 Patients US 80,000 Patients EU Acute Radiation Enteritis in Colorectal cancer 50,000 Patients US 50,000 Patients EU RiVax™ Ricin V
Slide 29: Investment Highlights
Investment Highlights i=} iverse pipeline with multiple potential value drivers in development Innovative products addressing high unmet medical needs Experienced management and Board of Directors Expertise in specialized development areas of GI, oncology and biodefense Potential for co-development
Slide 30: Thank You
THANK YOU iy